Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence
Perineural invasion (PNI) is a typical feature of pancreatic ductal adenocarcinoma (PDAC), which occurs in most cases. The embryonic protein Nodal plays a critical role in embryonic neural development and is overexpressed in human pancreatic cancer. In this study, we explored the contribution of Nodal to pancreatic cancer PNI and progression. We evaluated the function of Nodal in PNI by coculturing rat dorsal root ganglia and pancreatic cancer cells in vitro and performing cellular and molecular biology assays. The results illustrate that Nodal upregulates NGF (nerve growth factor), BDNF (brain-derived neurotrophic factor), and GDNF (glial cell line-derived neurotrophic factor) expression in pancreatic cancer cells and promotes cancer cell migration/invasion. Furthermore, in the in vitro 3D PNI model, Nodal enhances nerve outgrowth to pancreatic cancer cell colonies. Our study indicates that Nodal participates in tumor invasion by mediating neural and tumor cell signaling interactions, and inhibiting the expression of Nodal represents a potential strategy for targeting PNI in pancreatic cancer therapy.
Pancreatic cancer (PC) is one of the most lethal cancers with a dismal 5-year survival rate of about 10% . In particular, pancreatic ductal adenocarcinoma (PDAC) is the most common histological type with highly invasive and metastatic properties. Its poor prognosis is due to late diagnosis, early metastasis, and limited treatment options, which result in roughly equal mortality and morbidity in PC patients [2, 3]. Although surgical resection is considered the only possible cure for PC, only 20% of pancreatic cancer patients can undergo curative resection . Postoperative recurrence is the main factor leading to surgical failure, which occurs in up to 60% of patients. With current multimodal treatment, the median overall survival is only 11 months [5, 6].
Recent studies have found that perineural invasion (PNI) is a common feature of PC with an incidence of 87% [7–9]. PNI is characterized by tumor cell invasion in, around, and through the nerves while encroaching on at least 33% of its circumference or within any of the 3 layers of the nerve sheath . PNI is an independent risk factor for disease-free survival (DFS) and/or OS and can be used as a prognostic indicator. The absence of PNI has an independent protective effect on the long-term survival (more than 10 years) of PDAC patients. Whether pancreatic cancer patients are accompanied by PNI is one of the key references for guiding personalized antitumor treatment plans . PNI has been found in the early stages of pancreatic cancer and is related to pain [11, 12], local recurrence , metastasis [14, 15], and poor prognosis . Despite extensive knowledge of the clinical significance of PNI, its pathogenic mechanism remains unknown.
Nodal is a type of embryonic morphogen and a member of the transforming growth factor (TGF) beta superfamily. In humans, the Nodal gene is located on chromosome 10 and contains three protein-coding exon regions that are translated into a 347-amino acid proprotein. Nodal plays a crucial role during early embryonic development and is almost undetectable in normal human cells. During embryogenesis, Nodal signaling activates the differentiation process and eventually loses function after transcriptional silence . Nodal signaling plays an important role during neural development. Nodal influences neural tube closure by adjusting N-cadherin levels in zebrafish . Deficiencies in the Nodal signaling pathway potentially underlie human neural tube defects, such as exencephaly, a fatal condition characterized by an open neural tube in the anterior brain. Furthermore, numerous studies have revealed Nodal re-expression in several tumor types. The acquisition of Nodal expression is directly related to tumorigenesis, proliferation, invasion, and metastasis, EMT (epithelial-mesenchymal transition), and angiogenesis [16, 18].
Previous studies of Nodal in pancreatic cancer focused on its role in promoting stem cell-like phenotypes . However, the effect of Nodal on pancreatic cancer PNI remains unclear. In this study, we hypothesized that high expression of Nodal promotes nerve infiltration and local invasion of pancreatic cancer. The expression of neurotrophins is enhanced by Nodal and then promotes the growth of synapses toward pancreatic cancer cells. Besides, Nodal promotes the production of matrix metalloproteinases (MMPs), thereby promoting PNI via reducing the resistance of interstitial spaces between tumor cells and nerves.
2. Materials and Methods
2.1. Cell Lines, Culture Conditions, and Reagents
The human PC cell lines (BxPC3 and Panc-1) were obtained from the Chinese Academy of Sciences Cell Bank of Type Culture Collection, and they were cultured in the corresponding medium (Invitrogen) which contains 10% fetal bovine serum (FBS), 100 μg/ml penicillin-streptomycin. The cells were incubated at 37°C in a humidified atmosphere containing 5% CO2. Antibodies were purchased from the following sources: recombinant mature human Nodal (rhNodal) (R&D Systems) and its inhibitor SB431542 (Sigma-Aldrich); anti-MMP-9 (Bioworld); and anti-NGF, anti-BDNF, and anti-GDNF (Abcam).
Panc-1 and BxPc-3 were fixed in 4% paraformaldehyde for 20 min, and 3% H2O2 was added to quench the activity of endogenous peroxidase. Then, the samples were permeabilized with 0.5% Triton X 100 for 5 min and blocked with bovine serum albumin for 15 min at room temperature. Next, PC cells were incubated with the primary antibody at 4°C (overnight) and fluorescein-conjugated secondary antibodies (Jackson) for 1 h. DAPI was used to stain the nuclei for 5 min. The images were collected by a fluorescence microscope (Nikon).
2.3. RNAi Transfections
siRNA against Nodal (5′-AGACAUGAUCGUGGAAGAAtt-3′) and negative control (5′-CAUUUCGUCUGCCUCAUAUtt-3′) were purchased from GenePharm. Transfection was performed with Lipofectamine RNAi MAX Reagent (Invitrogen) according to the manufacturer’s instructions. After 48 h of transfection, the cells were used for further experiments.
2.4. Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were treated with corresponding agents for 24 h and then cultured in an FBS-free medium for 72 h. Then, the culture medium was collected and centrifuged at 1500 rpm for 5 min to remove particles. The supernatant was frozen at −80°C. The production of NGF in the supernatant was detected using a commercial ELISA kit (R&D Systems) according to the manufacturer’s instructions.
2.5. Western Blotting Analysis
Cells were lysed using RIPA which contained protease inhibitors (Roche). Relative proteins were resolved on a denaturing SDS polyacrylamide gel by electrophoresis and electrotransferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk for 2 h. Then, the membranes were incubated with corresponding primary antibodies against NGF, BDNF, GDNF, MMP-9, and β-actin (4°C, overnight) and hybridized to the appropriate secondary antibodies (room temperature, 1 h). β-actin served as the loading control. The probed proteins were detected by enhanced chemiluminescence (Millipore).
2.6. Cell Invasion Assay
The Transwell chamber (8.0 μm; Millipore) which was coated with 30 μl of Matrigel was placed into a 24-well culture plate. 5×104 PC cells were resuspended in DMEM (containing 1% FBS) with or without rhNodal and seeded in the upper chamber. Furthermore, 600 μl of DMEM medium (containing 20% FBS) was added to the lower chamber. The Transwell chamber was incubated for 24 h. Cells were fixed in methanol and stained with crystal violet. The number of invasion cells was counted under a light microscope (Nikon) in 10 randomly selected fields.
2.7. Dorsal Root Ganglion (DRG) Coculture Assay
Newborn rats were purchased from the Animal Center of the Medical College of Xi’an Jiaotong University and were sacrificed using carbon dioxide and sterilized with 75% ethanol. DRGs from the lumbar areas were dissected, stripped of meninges and nerve stumps, and then implanted into a drop of 50% Matrigel (BD Biosciences). After solidification, DMEM/F12 (containing 10% FBS) with or without rhNodal and/or Nodal inhibitor (SB431542) was carefully added, which was changed every 3 days under routine culture. Images were photographed by a light microscope (Nikon). For evaluating the coculture model, we defined the minimum distance between the edge of the cancer cells and the edge of DRG as parameter γ, the migration distance of cancer cells toward DRG as parameter α, and the DRG outgrowth length toward cancer cells as parameter β. Here, the invasion index = α/γ, and the DRG outgrowth index = ß/γ (Figure 1(d)). The migration distance was measured by the abovementioned images.
2.8. Statistical Analyses
For statistical analyses, the SPSS 13.0 software package was adopted. All the data were described by mean ± standard deviation (SD). The differences between the enumeration data were determined using the Pearson correlation coefficient or Fisher’s exact test. The differences between measurement data were determined using analysis of variance (ANOVA) followed by Bonferroni’s correction for multiple comparisons. P < 0.05 was considered significant.
3.1. Nodal Increases the Expression of Neurotrophins and Enhances Pancreatic Cancer Cell Invasion
To determine whether Nodal affects the expression of neurotrophins (NGF, BDNF, and GDNF) and MMP-9 in pancreatic cancer cells, Panc-1 and BxPC-3 cells were treated with rhNodal (0, 50, and 100 μM) for 24 h. Western blot analysis was used to evaluate NGF, BDNF, GDNF, and MMP-9 protein expression in pancreatic cancer cells. The results revealed that rhNodal increased the expression levels of NGF, BDNF, GDNF, and MMP-9 in a dose-dependent manner (Figure 2(a)). Furthermore, immunofluorescence results showed that NGF levels were markedly increased in Panc-1 and BxPC-3 cells following treatment with rhNodal (100 μM) for 24 h (Figure 2(b)). ELISA results confirmed that NGF secretion increased in Panc-1 cells treated with rhNodal (0, 50, and 100 μM), which is consistent with western blot results (Figure 2(c)). To elucidate the role of Nodal in pancreatic cancer cell invasion, Transwell chamber assays with Matrigel were performed. In the Transwell invasion assays, the invasion ability of pancreatic cancer cells treated with rhNodal (100 μM) was enhanced compared with the control group (Figure 2(d)). These data suggested that high Nodal expression levels upregulated neurotrophins and MMP-9 expression levels and subsequently increased pancreatic cancer cell invasion.
3.2. Nodal Knockdown Decreases the Expression of Neurotrophins and Inhibits Pancreatic Cancer Cell Invasion
To determine whether Nodal influences the expression of neurotrophins and invasion ability, we used Nodal siRNA to knock down Nodal. Three siRNA sequences were designed, and the efficiency of these siRNAs was evaluated by western blot (Figure 3(a)). SiRNA2 was selected for further experiments given its high-quality effect on knockdown the expression of Nodal. We found that the expression of neurotrophins (NGF, BDNF, and GDNF) and MMP-9 in Panc-1 and BxPC-3 cells was significantly decreased in the siNodal group compared to the siNC group (Figure 3(b)). Immunofluorescence results showed that NGF expression was reduced in pancreatic cancer cells after Nodal knockdown, and these results were consistent with western blot results (Figure 3(c)). In the Transwell invasion assays, siNodal inhibited the invasion ability of Panc-1 and BxPC-3 cells (Figure 3(d)). These data further proved that Nodal expression levels can influence neurotrophins and MMP-9 expression.
3.3. Nodal Inhibition Hampers the Infiltrative Growth of DRG Synapses
To investigate whether Nodal affects DRGs’ growth, DRGs were extracted from newborn rats and cultured in 24-well plates. Nodal with or without its inhibitors was added into the culture solution which was changed every two days to maintain the drug concentration in the culture solution. The outward growth of ganglion synapses was observed and recorded under a microscope every day. After 96 h of culture, the outward growth of DRG synapses in the rhNodal group was enhanced compared with that in the control group, but no significant difference was noted. However, upon inhibition of Nodal by SB431542, the outward growth of DRGs was significantly reduced compared with the rhNodal group (Figure 4). These data indicate that Nodal is a necessary but insufficient condition to cause synaptic growth.
3.4. Nodal Affects the Interaction between Pancreatic Cancer Cells and DRGs
We further wanted to demonstrate whether Nodal accelerates PNI of pancreatic cancer cells. An in vitro peripheral neural invasion model was created using pancreatic cancer cells with DRGs in Matrigel according to previous reported models [19, 20]. During the coculture period of pancreatic cancer cells (Panc-1 and BxPC-3) and DRGs, we found that the DRG synaptic boundary and pancreatic cancer cell boundary moved toward each other more obviously in the Nodal intervention group than in the control group. After 96 hours of coculture, the DRG outgrowth ratio and tumor invasion index were calculated. The calculation method of DRG growth rate and tumor invasion index refers to a previously reported method (Figure 1(d)) . The DRG outgrowth ratio and tumor invasion index of the rhNodal group increased faster than the control group (Figures 1(a) and 1(c)). The trend of growth between DRGs and pancreatic cancer cells was inhibited when Nodal was knockdown in pancreatic cancer cells by small interfering RNA (Figure 1(b)). Besides, the DRG outgrowth ratio and tumor invasion index were reduced in the siNodal group compared to those in the NC group (Figure 1(c)). The abovementioned results prove that Nodal acts on tumor cells, thereby affecting the interaction between tumor cells and DRGs.
Members of the TGFβ family, including bone morphogenetic proteins (BMPs), TGFβ, and Nodal/activin, whose functions vary with the cellular environment (including disease, local environment, and the characteristics and dosage of the ligand). As a versatile cytokine, TGFβ is proved to promote invasion and metastasis in many tumors. Our previous studies have shown that, as an activator of mesenchymal cells, TGFβ affects YAP expression, which in turn mediates CTGF (connective tissue growth factor) expression and activation of pancreatic cancer stellate cells . In the tumor microenvironment, Schwann cells are an important source of TGFβ in PDAC, and TGFβ signal activation in PDAC samples is positively correlated with peripheral infiltration . Nodal and activin bind to their coreceptors, activin-like (Alk) type I receptors Alk4/7, and Cripto-1 constitutes an important coreceptor for Nodal signaling. Recent studies showed that Nodal is aberrantly upregulated in many cancers, such as prostate cancer, bladder cancer, breast cancer, and colon cancer [24, 25]. Nodal expression is significantly increased in human pancreatic cancer tissues and pancreatic cancer cell lines and is related to the high grade of pancreatic cancer. Knockdown Nodal expression reverses the invasive phenotype of pancreatic cancer and significantly decreases the number and size of liver metastases . Ronaldo et al. examined pancreatic CSCs (cancer stem cells) from cell lines and primary tumor samples and found that they were highly enriched in Nodal/activin signals. Recombinant Nodal treatment enhances CSCs renewal and is blocked by the Alk receptor inhibitor SB431542 (specific to Alk4, Alk5, and Alk7) or the Nodal specific feedback inhibitor Lefty . In our study, we found Nodal can affect the expression of MMP9 and promote the invasion and metastasis of pancreatic tumor cells. A previous study reported that Nodal plays a role in temporal and spatial neurodevelopment by regulating the mesoderm , but whether Nodal participates in pancreatic cancer PNI is unclear. So, we further studied the role of Nodal in the nerve invasion of pancreatic cancer.
Although PNI is an independent risk factor for pancreatic cancer, due to the complexity of the tumor microenvironment and insufficient understanding of PNI, there is almost no treatment for PNI. Previous studies showed the function of PNI may be affected by molecules (such as involving neurotrophies and their receptors, cytokines, chemokines, and neurotransmitters), metabolism (such as serine metabolism), and cellular mechanisms (such as involving Schwann cells and macrophages) [28–30]. The neurotrophic factor protein family includes NGF, BDNF, and GDNF, which can induce the survival, development, and function of neurons. They can also be produced and secreted by PDAC cells and directly affect the interaction between cancer cells and nerves in the tumor microenvironment through corresponding receptors. The interaction between tumor and nerve creates a microenvironment that is more suitable for tumor survival, thereby promoting tumor invasion and metastasis [31, 32]. For example, PDAC is exogenously dependent on serine. When serine is lacking, tumor cells can secrete NGF and act on nerve cells to increase the secretion of serine . The combination of GDNF and GFRA1 (GDNF family receptor alpha-1) activates the RET signal. The GDNF-GFRA1-RET axis promotes cancer cell metastasis and matrix degradation by inducing cancer cell polarization and invasion pseudopodia . The mechanism of tumor pain caused by pancreatic cancer is complicated. Tumor cell invasion destroys the normal structure of the nerve sheath and produces various molecules, leading to neuropathic and inflammatory pain. Neurotrophins can contribute to cancer pain directly. GDNF is related to the degree of pain in patients with pancreatic cancer . By interacting with TRPV1 (transient receptor potential vanilloid 1), NGF can cause severe pain . Our study finds that after rhNodal treatment, neurotrophins (NGF, BDNF, and GDNF) significantly increased in pancreatic cancer cells, and vice versa. The growth of DRGs treated with rhNodal was not significantly different from that in the control group. Next, we evaluated the function of Nodal in PNI progression using a DRG and pancreatic cancer cell coculture system. The nerve outgrowth ratio and tumor invasion index were higher in the rhNodal group compared with those of the control group. In contrast, knockdown of Nodal expression using siRNA reverses the interaction between DRGs and pancreatic cancer cells. These findings reveal that Nodal acts on tumor cells to promote the secretion of neurotrophins, thereby promoting the occurrence of nerve infiltration. Previous studies on neurodevelopment have shown that Nodal inhibits the differentiation of embryonic stem cells into the neuroectoderm directly and is indispensable in neurodevelopment and growth . This finding may explain why the direct addition of rhNodal had no apparent effect on nerve growth, and the specific mechanism of its inhibitory function on nerve growth remains unclear.
Previous studies have shown that Nodal, expressed and secreted by pancreatic cancer stem cells and pancreatic stellate cells, plays an important role in maintaining the self-renewal and tumorigenicity of pancreatic cancer stem cells . Our research has proved the role of Nodal in tumor invasion, metastasis, and neural invasion of pancreatic cancer, but the exact mechanism of Nodal affecting MMP9 and neurotrophic factors is still unclear. In addition, whether Nodal is a key step in exerting nerve infiltration and tumor metastasis, its role in tumor stem cells, pancreatic stellate cells, and nerve infiltration needs to be further explored.
Nodal is highly expressed in pancreatic cancer cells and promotes the invasive ability of tumor cells and enhances the trend of chemotactic infiltration to nerves during PNI. Activating Nodal signaling could increase neurotrophic factor expression in cancer cells and promote nerve growth and chemotaxis to cancer cells (Figure 5). New therapies that target Nodal may be useful in the treatment of PNI in pancreatic cancer.
|PDAC:||Pancreatic ductal adenocarcinoma|
|NGF:||Nerve growth factor|
|BDNF:||Brain-derived neurotrophic factor|
|GDNF:||Glial cell line-derived neurotrophic factor|
|TGF:||Transforming growth factor|
|CSC:||Cancer stem cell|
|DRG:||Dorsal root ganglion|
|GFRA1:||GDNF family receptor alpha-1|
|CTGF:||Connective tissue growth factor|
|TRPV1:||Transient receptor potential vanilloid 1.|
Data supporting the findings of this study are available from the corresponding authors upon reasonable request.
All experimental protocols were approved by the Ethical Committee of the First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, China.
Part of the abstract of this manuscript was presented at the IAP (International Association of Pancreatology) in Shanghai .
Conflicts of Interest
The authors declare no conflicts of interest.
The authors are very grateful to Dr. Zheng Wang and Zheng Wu for their suggestions on this experiment. This research was funded by the National Natural Science Foundation of China (81702916, 82072699) and Natural Science Foundation of Shaanxi Province (2019JQ-959).
American Cancer Society, Pancreatic Cancer Early Detection, Diagnosis, and Staging, American, Cancer Society, Atlanta, 2018.
R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.View at: Publisher Site | Google Scholar
A. J. Grossberg, L. C. Chu, C. R. Deig et al., “Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma,” CA: A Cancer Journal for Clinicians, vol. 70, no. 5, pp. 375–403, 2020.View at: Publisher Site | Google Scholar
Z. Jutric and L. G. Melstrom, “New treatment options and management considerations in borderline resectable pancreatic cancer,” Oncology, vol. 31, no. 6, pp. 443–452, 2017.View at: Google Scholar
C. W. Tzeng, J. B. Fleming, J. E. Lee et al., “Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy,” International Hepato-Pancreato-Biliary Association, vol. 14, no. 6, pp. 365–372, 2012.View at: Publisher Site | Google Scholar
H. J. Yoo, M. W. You, D. Y. Han, J. H. Hwang, and S. J. Park, “Tumor conspicuity significantly correlates with postoperative recurrence in patients with pancreatic cancer: a retrospective observational study,” Cancer Imaging, vol. 20, no. 1, 46 pages, 2020.View at: Publisher Site | Google Scholar
W. Alrawashdeh, R. Jones, L. Dumartin et al., “Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling,” Molecular Oncology, vol. 13, no. 5, pp. 1075–1091, 2019.View at: Publisher Site | Google Scholar
N. R. Jurcak, A. A. Rucki, S. Muth et al., “Axon guidance molecules promote perineural invasion and metastasis of orthotopic pancreatic tumors in mice,” Gastroenterology, vol. 157, no. 3, pp. 838–850, 2019.View at: Publisher Site | Google Scholar
J. Li, R. Kang, and D. Tang, “Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma,” Cancer Communications, vol. 41, no. 8, pp. 642–660, 2021.View at: Publisher Site | Google Scholar
C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, and D. Albo, “Perineural invasion in cancer: a review of the literature,” Cancer, vol. 115, no. 15, pp. 3379–3391, 2009.View at: Publisher Site | Google Scholar
J. Nigri, M. Gironella, C. Bressy et al., “PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker,” Cellular and Molecular Life Sciences, vol. 74, no. 22, pp. 4231–4243, 2017.View at: Publisher Site | Google Scholar
L. Han, J. Jiang, M. Xue et al., “Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor,” Regional Anesthesia and Pain Medicine, vol. 45, no. 2, pp. 137–144, 2020.View at: Publisher Site | Google Scholar
J. Yao, X. F. Hu, X. S. Feng, and S. G. Gao, “Pleiotrophin promotes perineural invasion in pancreatic cancer,” World Journal of Gastroenterology, vol. 19, no. 39, pp. 6555–6558, 2013.View at: Publisher Site | Google Scholar
Y. H. Yang, J. B. Liu, Y. Gui, L. L. Lei, and S. J. Zhang, “Relationship between autophagy and perineural invasion, clinicopathological features, and prognosis in pancreatic cancer,” World Journal of Gastroenterology, vol. 23, no. 40, pp. 7232–7241, 2017.View at: Publisher Site | Google Scholar
C. Huang, Y. Li, Y. Guo et al., “MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells,” Theranostics, vol. 8, no. 11, pp. 3074–3086, 2018.View at: Publisher Site | Google Scholar
A. Sandomenico and M. Ruvo, “Targeting nodal and cripto-1: perspectives inside dual potential theranostic cancer biomarkers,” Current Medicinal Chemistry, vol. 26, no. 11, pp. 1994–2050, 2019.View at: Publisher Site | Google Scholar
L. M. Kindt, A. R. Coughlin, T. R. Perosino, H. N. Ersfeld, M. Hampton, and J. O. Liang, “Identification of transcripts potentially involved in neural tube closure using RNA sequencing,” Genesis, vol. 56, no. 3, Article ID e23096, 2018.View at: Publisher Site | Google Scholar
W. Duan, R. Li, J. Ma et al., “Overexpression of nodal induces a metastatic phenotype in pancreatic cancer cells via the smad2/3 pathway,” Oncotarget, vol. 6, no. 3, pp. 1490–1506, 2015.View at: Publisher Site | Google Scholar
D. A. Tonge, J. P. Golding, M. Edbladh, M. Kroon, P. E. R. Ekström, and A. Edström, “Effects of extracellular matrix components on axonal outgrowth from peripheral nerves of adult animals in vitro,” Experimental Neurology, vol. 146, no. 1, pp. 81–90, 1997.View at: Publisher Site | Google Scholar
T. Qin, J. Li, Y. Xiao et al., “Honokiol suppresses perineural invasion of pancreatic cancer by inhibiting SMAD2/3 signaling,” Frontiers in Oncology, vol. 11, 2021.View at: Publisher Site | Google Scholar
X. Li, Z. Wang, Q. Ma et al., “Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer,” Clinical Cancer Research, vol. 20, no. 16, pp. 4326–4338, 2014.View at: Publisher Site | Google Scholar
Z. Jiang, C. Zhou, L. Cheng et al., “Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions,” Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, 69 pages, 2018.View at: Publisher Site | Google Scholar
E. Roger, S. Martel, A. Bertrand-Chapel et al., “Schwann cells support oncogenic potential of pancreatic cancer cells through TGFβ signaling,” Cell Death & Disease, vol. 10, pp. 886–12, 2019.View at: Publisher Site | Google Scholar
A. Alwhaibi, A. Verma, S. Artham, M. S. Adil, and P. R. Somanath, “Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis,” Biochemical Pharmacology, vol. 168, pp. 1–13, 2019.View at: Publisher Site | Google Scholar
S. H. Chen, B. Y. Zhang, B. Zhou, C. Z. Zhu, L. Q. Sun, and Y. J. Feng, “Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche,” American Journal of Cancer Research, vol. 9, no. 1, pp. 1–21, 2019.View at: Google Scholar
E. Lonardo, P. C. Hermann, M. T. Mueller et al., “Nodal/activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy,” Cell Stem Cell, vol. 9, no. 5, pp. 433–446, 2011.View at: Publisher Site | Google Scholar
N. Gonsar, A. Coughlin, J. A. Clay-Wright, B. R. Borg, L. M. Kindt, and J. O. Liang, “Temporal and spatial requirements for nodal-induced anterior mesendoderm and mesoderm in anterior neurulation,” Genesis, vol. 54, no. 1, pp. 3–18, 2016.View at: Publisher Site | Google Scholar
Q. Xu, Z. Wang, X. Chen et al., “Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer,” Oncotarget, vol. 6, no. 7, pp. 4717–4732, 2015.View at: Publisher Site | Google Scholar
D. Liang, S. Shi, J. Xu et al., “New insights into perineural invasion of pancreatic cancer: more than pain,” Biochimica et Biophysica Acta, vol. 1865, no. 2, pp. 111–122, 2016.View at: Google Scholar
B. Xin, X. He, J. Wang et al., “Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer,” Pancreatology, vol. 16, no. 6, pp. 1005–1014, 2016.View at: Publisher Site | Google Scholar
L. C. M. Antunes, A. Cartell, C. B. de Farias, R. M. Bakos, R. Roesler, and G. Schwartsmann, “Tropomyosin-related kinase receptor and neurotrophin expression in cutaneous melanoma is associated with a poor prognosis and decreased survival,” Oncology, vol. 97, no. 1, pp. 26–37, 2019.View at: Publisher Site | Google Scholar
J. K. Moraes, V. P. Wagner, F. P. Fonseca et al., “Activation of BDNF/TrkB/Akt pathway is associated with aggressiveness and unfavorable survival in oral squamous cell carcinoma,” Oral Diseases, vol. 25, no. 8, pp. 1925–1936, 2019.View at: Publisher Site | Google Scholar
I. Lohse and S. P. Brothers, “Pathogenesis and treatment of pancreatic cancer related pain,” Anticancer Research, vol. 40, no. 4, pp. 1789–1796, 2020.View at: Publisher Site | Google Scholar
E. Y. Lian, B. D. Hyndman, S. Moodley, S. M. Maritan, and L. M. Mulligan, “RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma,” Oncogene, vol. 39, no. 41, pp. 6493–6510, 2020.View at: Publisher Site | Google Scholar
Q. Zeng, Y. Cheng, Q. Zhu et al., “The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer,” Journal of International Medical Research, vol. 36, no. 4, pp. 656–664, 2008.View at: Publisher Site | Google Scholar
Y. Zhu, T. Colak, M. Shenoy et al., “Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis,” Gastroenterology, vol. 141, no. 1, pp. 370–377, 2011.View at: Publisher Site | Google Scholar